|
PHARMACOLOGICAL ACTION:
Deblaston contains the antimicrobial substance Pipemidic acid
which is related to Nalidixic acid.
Pipemidic acid is absorbed from the intestine, reaches effective
levels in the tissues, is excreted in the urine in high
concentrations in the active form and is metabolized only to a
small extent.
In-vitro Deblaston is effective against Gram negative organisms,
except Serratia marcescens, also effective against Pseudomonas
aeruginosa.
It is not effective against Gram positive organisms especially
Strep. faecalis.
INDICATIONS:
Urethritis, cystitis, pyelonephritis and acute prostatitis due to
susceptible organisms.
CONTRA-INDICATIONS:
Deblaston should not be administered to children or adolescents
during the growth phase and is contra-indicated in pregnancy and
lactation.
Deblaston is contra-indicated in severe renal failure with anuria
or oliguria (serum creatinine above 3 mg%, creatinine clearance
below 10 mL/min.).
Contra-indicated in patients with hepatic disease or patients in
whom hepatic dysfunction develops on treatment.
DOSAGE AND DIRECTIONS FOR USE:
Two capsules should be taken twice daily - morning and evening
with meals - for at least 5 days. Treatment should not exceed 10
days in duration. At the end of this time, it is advisable to
change to another anti-bacterial agent so as to counter any
possible development of resistance on the part of the
micro-organisms.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Gastro-intestinal symptoms such as anorexia, gastric discomfort,
abdominal distention and pain, nausea, vomiting, thirst, diarrhoea,
constipation, fatigue, dizziness, headache and stomatitis may
occur. There have been reports of skin reactions (pruritis,
erythema and other eruptions). Anaphylactic shock can occur.
During treatment excessive exposure to sunlight or ultraviolet
radiation should be avoided.
In the event of an allergic reaction, treatment should be
discontinued at once and your doctor should be consulted.
As adequate information is not yet available regarding the use of
Deblaston in patients with existing epilepsy or epileptiform
conditions, it should not be given to such patients without
careful consideration of the risks and the benefits.
The development of cross-resistance between Pipemidic acid and
Nalidixic acid is in principle to be expected. However, mutants
resistant to Nalidixic acid may be sensitive to Pipemidic acid.
Elevation of BUN, creatine levels, SGOT and SGPT as well as a
decrease in leucocyte counts can occur. False high values of urine
protein are sometimes recorded by certain measuring methods. To
avoid this it is recommended that the boiling method or the test
paper method be used.
|
Quality-tablets.jpg)
